BlueCross BlueShield
Federal Employee Program
Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.30.107

Section:	Prescription Drugs	**Effective Date:**	July 31, 2026
Subsection:	Endocrine and Metabolic Drugs	**Original Policy Date:**	July 31, 2026
Subject:	Lumvoa	**Page:**	1 of 3

Last Review Date: December 11, 2026

Lumvoa

Description

Lumvoa (veligrotug-vvze)

Background
Lumvoa (veligrotug-vvze) is a humanized IgG1 monoclonal antibody that binds to insulin-like growth factor-1 receptor (IGF-1R) and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation. Lumvoa's mechanism of action in patients with thyroid eye disease has not been fully characterized (1).

Regulatory Status
FDA-approved indication: Lumvoa is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration (1).

Lumvoa contains warnings regarding infusion reactions, inflammatory bowel disease, hyperglycemia, and hearing impairment including hearing loss (1). Lumvoa may cause severe or permanent hearing impairment including hearing loss. Assess patients' hearing before, during, and after treatment with Lumvoa.

Lumvoa may cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should undergo pregnancy testing prior to treatment and be advised to use an effective method of contraception during treatment with Lumvoq and for at least 6 months after the last dose (1).

The safety and effectiveness of Lumvoa in pediatric patients less than 18 years of age have not been established (1).

Related policies
Tepezza

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Lumvoa may be considered **medically necessary** if the conditions indicated below are met.

Lumvoa may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Thyroid eye disease

AND ALL of the following:

1. Prescriber agrees to monitor for infusion reactions
2. Prescriber agrees to monitor blood glucose
3. Prescriber agrees to monitor for hearing impairment
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Lumvoa and for 6 months after the last dose

Prior – Approval *Renewal* Requirements

None

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 5 intravenous infusions (weight-based)

Duration 6 months (only one PA approval per lifetime)

Prior – Approval *Renewal* Limits

None

Rationale

Summary
Lumvoa (veligrotug-vvze) is an insulin-like growth factor-1 receptor inhibitor (IGF-1R) injection, given via intravenous infusion. Lumvoa is indicated in patients with thyroid eye disease regardless of thyroid eye disease activity or duration. The safety and effectiveness of Lumvoa in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Lumvoa while maintaining optimal therapeutic outcomes.

References

1. Lumvoa [package insert]. Waltham, MA: Viridian Therapeutics, Inc.; June 2026.

Policy History

Date	Action
July 2026	Addition to PA

Keywords

This policy was effective with interim approval on July 31, 2026 and will be reviewed by the FEP® Pharmacy and Medical Policy Committee on December 11, 2026.